Showing papers in "Journal of Cardiac Failure in 2020"

TL;DR: High troponin levels are associated with increased mortality in patients with COVID-19, implicating myocardial injury as a possible pathogenic mechanism contributing to severe illness and mortality.

TL;DR: This scientific statement outlines the benefits and challenges of VV, enumerates changes in policy and reimbursement that have increased the feasibility of VVs during the COVID-19 era, describes platforms and models of care for VVs, and provides a vision for the future.

TL;DR: It is found that patients with ECG findings of both left sided heart disease (APCs, IVB, repolarization abnormalities) and right sided disease (RBBB) have higher odds of death.

TL;DR: There has been a significant reduction in the number of patients hospitalized for HF during the COVID-19 pandemic, based on observations from a large academic medical center.

TL;DR: In ATTR-CM, diflunisal treatment resulted in measurable differences in some parameters of cardiac structure and function after only 1 year of administration, including global longitudinal strain (GLS).

TL;DR: The available evidence indicates that changes in xanthine oxidase and uric acid are biomarkers of oxidative stress (particularly in heart failure) and that xanthin oxidase may provide an important source of nitric oxide that quenches the injurious effects of reactive oxygen species.

TL;DR: Black men may be at increased risk for Covid-19 among patients with OHT, and Elevated inflammatory markers on presentation appear to be associated with more severe illness.

TL;DR: Elamipretide was well tolerated but did not improve LVESV at 4 weeks in stable HFrEF patients compared with placebo, and no significant differences in change in left ventricular end diastolic volume andleft ventricular ejection fraction were observed between placebo and either of the elamipretides group.

TL;DR: A more predominant systemic microvascular endothelial dysfunction and inflammation linked to increased fibrosis in HFpEF compared with HFrEF is suggested and is associated with indices of increased inflammation and oxidative stress, impaired lipid metabolism, increased collagen synthesis, and downregulated nitric oxide signaling.

TL;DR: Clinical assessment of patients with advanced heart failure presenting with ADHF has low accuracy across all training levels, with exaggerated rates of misrecognition of the most high-risk patients.

TL;DR: In a rabbit model with chronic MI and HF, LCZ696 therapy ameliorated post-infarct heart function impairment, electrophysiological remodeling and altered CaMKII-p expression, leading to reduced VA inducibility.

TL;DR: This trial did not confirm that the ACP program was effective in facilitating EOL care consistent with HF patients' preferences, but led to short-term improvements in the decision-making.

TL;DR: Obese HFpEF patients experience greater deterioration in renal function during decongestion compared to non-obese patients, and further study is needed to elucidate the complex relationships between volume distribution, cardiorenal hemodynamics and adiposity.

TL;DR: Clinical data are supportive of such an association and future studies should further investigate the effects of zinc supplementation on outcomes in HF patients, as several pathobiological pathways to link zinc deficiency with the development and deterioration of HF are presented.

TL;DR: Patients with MethHF are frequently encumbered by psychiatric and substance abuse co-morbidities, and carry a substantial risk of heart failure readmission and mortality, and comprehensive efforts are needed to stem this emerging epidemic.

TL;DR: The high prevalence of CMD and its CV and HF specific prognostic role suggest CMD may be a potential treatment target in HFpEF.

TL;DR: In this contemporary HIV+ population receiving antiretroviral therapy, DD was associated with multiple alterations in cardiac structure and function, including myocardial fibrosis and left atrial abnormalities, and worse quality of life.

TL;DR: TNF alpha inhibitor treatment guided by FDG-PET may minimize corticosteroid use and effectively reduce cardiac inflammation without significant adverse effect on cardiac function.

TL;DR: The metabolic profile can complement NT-proBNP in determining disease severity in non-ischemic dilated cardiomyopathy and reveal potential alternative treatment targets in advanced symptomatic DCM.

TL;DR: Obesity alone should not be considered a contraindication for VAD therapy in contemporary era and strategies should be developed to promote weight loss which occurs infrequently in obese patients.

TL;DR: Renal function following LVAD implantation is characterized by improvement, steady state and subsequent deterioration, including improvement of kidney function in every preoperative CKD stage group.

TL;DR: S3 measured from implantable cardiac devices has stronger prognostic power to predict episodes of future HF events than that of auscultation and is attributed to both continuous monitoring and sub-audible measuring capability.

TL;DR: NICOM technology is not a reliable method of measuring CO in patients with decompensated heart failure and CS and is not approved by FDA for measurement of stroke volume.

TL;DR: Quantitative assessment of intravascular volume demonstrates for the first time that severe (not mild or moderate) volume expansion is highly common in obese ambulatory chronic HF patients, which supports an evolving concept of an obesity-specific HF phenotype.

TL;DR: Listening to recorded classical music is a feasible, non-invasive, safe, and inexpensive intervention, able to improve QOL in patients with HF in the home-care setting.

TL;DR: This analysis confirms the findings in a separate LVAD cohort, and presents a novel, user-friendly mortality prediction model incorporating pectoralis muscle measures, which had favorable discrimination in this multicenter dataset.